产品介绍 评论(0)
宿主来源
Rabbit抗原名称
VEGF-A分子别名
Vascular endothelial growth factor A, long form; L-VEGF; Vascular permeability factor (VPF); VEGF; VEGFA免疫原
Recombinant Protein克隆号
SDT-3855-2抗体类型
Recombinant mAb抗体同种型
IgG反应种属 ?
Hu, Ms预测反应种属
(反应种属缩写表)Rt交叉反应
It shows good reactivity with VEGF121 and no cross reactivity against Human TNF-α.
纯化方式
Protein A浓度
2 mg/ml纯度
>95% by HPLC标记
Unconjugated性状
Liquid缓冲体系
PBS pH7.4, 0.03% Proclin 300
储存条件
12 months from date of receipt, 2 to 8 °C as supplied
应用
Sandwich ELISA
CLIA
Vascular Endothelial Growth Factor A (VEGFA) is a pivotal biomarker in clinical diagnosis, primarily valued for its central role in angiogenesis and disease progression. As a key regulator of new blood vessel formation, its expression is frequently dysregulated in numerous pathologies, especially solid tumors.
In oncology, elevated VEGFA levels in serum or tumor tissues strongly correlate with tumor growth, metastasis, and poor prognosis, making it a critical prognostic indicator. For example, in non-small cell lung cancer, VEGFA expression helps predict disease progression and assess patient outcomes. Beyond diagnosis, it serves as a predictive biomarker for anti-angiogenic therapies, such as bevacizumab, enabling personalized treatment strategies.
Moreover, VEGFA’s diagnostic significance extends to non-neoplastic conditions, including cardiovascular diseases, diabetic retinopathy, and inflammatory disorders, where aberrant angiogenesis contributes to pathogenesis. Its detection, via immunohistochemistry or liquid biopsies, offers a minimally invasive means of disease monitoring. In summary, VEGFA is an indispensable tool in clinical diagnostics, linking disease detection, prognosis, and therapeutic guidance.
配对推荐







评论(0)